Attached files
| file | filename |
|---|---|
| 8-K - THERALINK TECHNOLOGIES, INC. | form8-k.htm |
| EX-10.1 - THERALINK TECHNOLOGIES, INC. | ex10-1.htm |
September 4, 2015
Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, NE
Washington, DC 20549
| Re: | OncBioMunePharmaceuticals, Inc. (f.k.a. Quint Media, Inc.) |
| File Reference No. 000-52218 |
We were previously the independent registered public accounting firm for OncBioMune Pharmaceuticals, Inc. (f.k.a. Quint Media, Inc.) and under the date of May 28, 2015, we reported on the financial statements of Quint Media, Inc. as of February 28, 2015 and for the year then ended.
On September 4, 2015 we were dismissed as the independent registered public accounting firm. We have read OncBioMune Pharmaceuticals, Inc’s. (f.k.a. Quint Media, Inc.) disclosures included in Item 4.01 “Changes in Registrant’s Certifying Accountant” on OncBioMune Pharmaceuticals, Inc’s. (f.k.a. Quint Media, Inc.) Form 8-K dated August 27, 2015 to be filed with the Securities and Exchange Commission and we agree with such statements as they pertain to Salberg & Company, P.A.
Very truly yours,
SALBERG & COMPANY, P.A.
Certified Public Accountants and Consultants
2295 NW Corporate Blvd., Suite 240 ● Boca Raton, FL 33431-7328
Phone: (561) 995-8270 ● Toll Free: (866) CPA-8500 ● Fax: (561) 995-1920
www.salbergco.com ● info@salbergco.com
Member National Association of Certified Valuation Analysts ● Registered with the PCAOB
Member CPAConnect with Affiliated Offices Worldwide ● Member AICPA Center for Audit Quality